Evidence map›Paper›PMID 38932521›Full record

ArticleCancer science2024

FoxG1/BNIP3 axis promotes mitophagy and blunts cisplatin resistance in osteosarcoma.

Baolong Pan, Yan Li, Huiyun Han, Lu Zhang, Xuemei Hu, Yanyu Pan, Zhuohui Peng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Baolong PanHealth Examination Center, Sixth Affiliated Hospital of Kunming Medical University, Yuxi, Yunnan, China.ORCID https://orcid.org/0009-0007-3905-4072
Yan LiDepartment of Neuroendocrine, Yuxi Children's Hospital, Yuxi, Yunnan, China.
Huiyun HanDepartment of Pharmacy, Kunming Children's Hospital, Kunming, Yunnan, China.
Lu ZhangDepartment of Asset Management, Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Xuemei HuHealth Examination Center, Sixth Affiliated Hospital of Kunming Medical University, Yuxi, Yunnan, China.
Yanyu PanCollege of Basic Medical Sciences, Naval Medical University, Shanghai, China.
Zhuohui PengSecond Department of Orthopedics, Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.

Funding

National Natural Science Foundation of China 81960487
6 · The paper itself

Abstract

Cisplatin (CDDP) is a commonly used chemotherapeutic for osteosarcoma (OS) patients, and drug resistance remains as a major hurdle to undermine the treatment outcome. Here, we investigated the potential involvement of FoxG1 and BNIP3 in CDDP resistance of OS cells. FoxG1 and BNIP3 expression levels were detected in the CDDP-sensitive and CDDP-resistant OS tumors and cell lines. Mitophagy was observed through transmission electron microscope analysis. The sensitivity to CDDP in OS cells upon FoxG1 overexpression was examined in cell and animal models. We found that FoxG1 and BNIP3 showed significant downregulation in the CDDP-resistant OS tumor samples and cell lines. CDDP-resistant OS tumor specimens and cells displayed impaired mitophagy. FoxG1 overexpression promoted BNIP3 expression, enhanced mitophagy in CDDP-resistant OS cells, and resensitized the resistant cells to CDDP treatment in vitro and in vivo. Our data highlighted the role of the FoxG1/BNIP3 axis in regulating mitophagy and dictating CDDP resistance in OS cells, suggesting targeting FoxG1/BNIP3-dependent mitophagy as a potential strategy to overcome CDDP resistance in OS.

Indexed as

Bone NeoplasmsCisplatinDrug Resistance, NeoplasmForkhead Transcription FactorsMembrane ProteinsMitophagyNerve Tissue ProteinsOsteosarcomaProto-Oncogene ProteinsAnimalsAntineoplastic AgentsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleAntineoplastic AgentsBNIP3 protein, humanCisplatinForkhead Transcription FactorsFOXG1 protein, humanMembrane ProteinsNerve Tissue ProteinsProto-Oncogene ProteinsBNIP3cisplatin (CDDP)drug resistanceFoxG1mitophgyosteosarcoma (OS)

Identifiers

PMID38932521
PMCPMC11309937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.